Tumor Response Predicts Survival Time of Nivolumab Monotherapy for Advanced Gastric Cancer: A Subgroup Analysis of the DELIVER Trial (JACCRO GC-08).

Yu SunakawaYasuhiro SakamotoRyohei KawabataAtsushi IshiguroYusuke AkamaruYosuke KitoMasazumi TakahashiJin MatsuyamaHiroshi YabusakiAkitaka MakiyamaTakahisa SuzukiMasahiro TsudaHisateru YasuiJun HiharaAtsushi TakenoEisuke InoueWataru IchikawaMasashi Fujii

Published in: The oncologist (2024)

The final analysis confirmed the efficacy of nivolumab monotherapy for patients with advanced GC in routine clinical practice. The exploratory analysis indicated that increasing DpR was associated with longer median PFS and OS in nivolumab treatment at a later-line setting.

Keyphrases

clinical practice
combination therapy
clinical trial
open label
phase iii
randomized controlled trial
study protocol
neoadjuvant chemotherapy
radiation therapy
simultaneous determination
liquid chromatography